Company / Net Debt per Share
Sarepta Therapeutics Net Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$6.82
FY2025
5-year range
-$19.56 / $9.20
FY2021-FY2025
Trend
-1973.6%
vs FY2024
Sector context
#79 of 82
Health Care
What the data says
Net Debt per Share changed -1974% YoY in FY2025, a notable deviation from the 7-year average annual change of -617%.
Based on SEC 10-K filings.
-6.82 in FY2025.
Improved from $9.20 to $-6.82 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 82This company -$6.82 Sector average $13.70
▼
-149.8% below sector average
Key checks
Key Insights
- In FY2025, net debt per share decreased 1973.6% year-over-year.
- Ranks #79 out of 82 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2023.
- Lowest net debt per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.82 | -1973.6% |
| FY2024 | $0.36 | -96.0% |
| FY2023 | $9.20 | +240.3% |
| FY2022 | -$6.56 | +66.5% |
| FY2021 | -$19.56 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $0.77 | +124.9% |
| FY2017 | -$3.08 | -34.1% |
| FY2016 | -$2.30 | -81.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026